________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
LEQVIO® is a first-in-class LDL-C-lowering therapy,1–4 with the convenience of
- HCP-administered
- Subcutaneous injection
- No refrigeration required
- Fixed dose
- No additional monitoring blood tests mandated†
- Does not add to pill burden
*After an initial dose, LEQVIO® is administered again at 3 months, followed by every 6 months.1,2
†Beyond what is already clinically indicated for your patient.
Watch the short video below to learn more about LEQVIO® administration, including a step-by-step guide for injection.
Subcutaneous administration of LEQVIO®:1,2
The recommended dose of LEQVIO® is 284 mg, administered via a single pre-filled syringe: initially, again at 3 months, and thereafter every 6 months.
LEQVIO® should be used with caution in patients with severe hepatic impairment and severe renal impairment.
For full information on LEQVIO® (inclisiran) dosing and administration, please refer to the SmPC.
Additional dosing and administration information1,2
No dose adjustments are required for patients with mild or moderate hepatic impairment, mild, moderate or severe renal impairment or end-stage renal disease, or elderly patients.
Check the LEQVIO® solution for injection visually before administration – it should be clear, colourless to pale yellow and essentially free of particles. If the solution contains visible particulate matter, the solution should not be used.
LEQVIO® is administered by a healthcare professional into the abdomen, upper arm or thigh.
Areas to avoid: active skin disease or injury (e.g. sunburns, skin rashes, inflammation, skin infections).
If a planned dose is missed by less than 3 months, LEQVIO® should be administered and dosing continued according to the patient's original schedule. If a planned dose is missed by more than 3 months, a new dosing schedule should be started – LEQVIO® should be administered initially, again at 3 months, followed by every 6 months.
For further information, please refer to the SmPC.
With over 12,000 patient-years exposure and >20,000 injections, the safety profile of LEQVIO® remains consistent, with no new safety signals identified in the ORION-8 open-label extension study‡5
With straightforward twice-yearly maintenance dosing, LEQVIO® can be administered during existing patient appointments1,2
Explore LEQVIO® eligibility criteria for primary care and secondary care
‡A pooled cohort of 3274 patients treated with LEQVIO® with an assumed dosing frequency of two injections per year and an average treatment duration of 3.7 years.5
HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol.
References
- LEQVIO® Great Britain. Summary of Product Characteristics.
- LEQVIO® Northern Ireland. Summary of Product Characteristics.
- Stoekenbroek RM, et al. Future Cardiol 2018;14(6):433–442.
- Klinovski M, et al. Inclisiran: a small interfering RNA molecule for treating hypercholesterolemia. Ottawa: CADTH; 2019. CADTH Issues in Emerging Health Technologies; Issue 180.
- Wright RS, et al. Oral presentation. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. ESC Congress 2023. Amsterdam, The Netherlands, 25–28 August 2023.
LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.